Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DRRX |
---|---|---|
09:32 ET | 817 | 0.8711 |
11:31 ET | 100 | 0.91 |
11:45 ET | 400 | 0.91 |
12:16 ET | 500 | 0.89125 |
12:45 ET | 9800 | 0.8701 |
01:01 ET | 100 | 0.8798 |
01:03 ET | 735 | 0.8701 |
01:53 ET | 2127 | 0.8803 |
02:00 ET | 115 | 0.8712 |
02:09 ET | 192 | 0.8973 |
02:24 ET | 250 | 0.8712 |
02:38 ET | 100 | 0.8949 |
02:51 ET | 100 | 0.8899 |
03:07 ET | 200 | 0.8798 |
03:14 ET | 499 | 0.8715 |
03:32 ET | 100 | 0.8849 |
03:38 ET | 1082 | 0.885 |
03:43 ET | 300 | 0.9021 |
03:45 ET | 3875 | 0.91 |
03:48 ET | 7839 | 0.91 |
03:54 ET | 300 | 0.913799 |
03:57 ET | 200 | 0.9139 |
03:59 ET | 200 | 0.9159 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
DURECT Corp | 27.4M | -0.8x | --- |
Spruce Biosciences Inc | 28.9M | -0.6x | --- |
VBI Vaccines Inc | 16.8M | -0.1x | --- |
Aspira Women's Health Inc | 42.0M | -1.9x | --- |
Tonix Pharmaceuticals Holding Corp | 13.5M | 0.0x | --- |
Palatin Technologies Inc | 27.9M | -0.7x | --- |
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.4M |
---|---|
Revenue (TTM) | $8.5M |
Shares Outstanding | 31.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.94 |
EPS | $-1.12 |
Book Value | $0.49 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -431.49% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.